Anti-Human GAPDH (Clone CPTC-GAPDH-1) – Purified No Carrier Protein

GAPDH synthetic peptide GALQNIIPASTGAAK

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

EB0959-5A11-H2/K4 activity is directed against human GAPDH peptide sequence GALQNIIPASTGAAK.

CPTC-GAPDH-1

GAPDH is involved in many cellular processes including glycolysis, DNA repair, tRNA export, membrane fusion and transport, cytoskeletal dynamics, and cell death¹. The functions of GAPDH differ based on its compartmental localization. In the cytoplasm, under basal conditions, GAPDH is an essential enzyme of glycolysis, converting glyceraldehyde-3-phosphate to D- glycerate 1,3-bisphospate and mediating the formation of NADH and ATP. However, under oxidative stress, posttranslational modifications allow GAPDH to shift metabolism from anaerobic respiration to the pentose phosphate pathway, thereby regulating oxidation/reduction balance. Additionally, cytosolic GAPDH facilitates microtubule bundling, actin polymerization, and membrane fusion and trafficking. In the mitochondria, GAPDH levels are low under basal conditions but elevated in response to stress and can lead to pro-apoptotic mitochondrial membrane permeabilization or recovery from mitochondrial outer-membrane permeabilization, depending on conditions. In the nucleus, during cellular stress, GAPDH participates in cell death/dysfunction and DNA repair. Increased GAPDH is associated with neurodegenerative disorders¹ and cancer² and is a target of related therapies.

EB0959-5A11-H2/K4 was generated in rabbit for use in immuno-MRM assays using a synthetic peptide derived from human GAPDH, GALQNIIPASTGAAK³. EB0959-5A11-H2/K4 has high affinity binding to full length, recombinant GAPDH in surface plasmon resonance assays using a protein A biosensor chip⁴. EB0959-5A11-H2/K4 can also detect GAPDH by immunohistochemistry, immunofluorescence, NCI60 protein array, and Western blotting and can be used to purify GAPDH by immunoprecipitation.

The majority of GAPDH localizes to the cytoplasm. GAPDH can also be found in the nucleus, mitochondria, and small vesicular fractions. GADPH undergoes subcellular redistribution in response to various stressors, such as oxidative stress.

SIAH1, TPPP

1 Tristan C, Shahani N, Sedlak TW, et al. Cell Signal. 23(2):317-323. 2011.
2 Butera G, Mullappilly N, Masetto F, et al. Int J Mol Sci. 20(9):2062. 2019.
3 Whiteaker JR, Lundeen RA, Zhao L, et al. Front Immunol. 12:765898. 2021.
4 https://antibodies.cancer.gov/detail/CPTC-GAPDH-1